IMMX Corporate Finance & Strategy Internship - 2026 Summer

Corporate Finance & Strategy Internship - 2026 Summer

Location: Los Angeles, CA. On-site

Timing: 2026 Summer

Our Values

· Integrity

· Intelligence

· Initiative

What You Will Do

• Create and complete internal financial models and presentations
• Pipeline - Participate in determining development strategy for pipeline therapeutic candidates
• Participate in developing corporate strategy for possible new therapeutic pipeline
• Create and complete proforma models to evaluate opportunities

What We Look For

Rising Senior - Undergraduate College Degree, or recent graduate

Masters Student between year 1 and two, or recent graduate

MD or PHD Student close to graduation, or recent graduate

A plus:

• prior investment banking / equity research / private equity / management consulting experience
• Prior Scientific Research Publications, Good Laboratory Practices, Experience in Early Drug Development

About Immix

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is the global leader in relapsed/refractory AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.